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Today, liver resection represents one of the most effective therapies in the treatment of 
defined liver diseases, particularly for hepatocellular carcinomas, liver metastases and 
tumors originating from the bile ducts. There have been a number of improvements in the 
technique but the use of kellyclasia associated with meticulous control of hemostasis and 
biliostasis appears to be more effective and efficient. The procedure is still burdened with 
some postoperative complications, the more characteristic of which are liver insufficiency, 
biliary leakage and ascites. Several neoplastic diseases, both primitive and secondary, 
can benefit from  this therapy with substantial improvement of long-term survival, and a 
notable change in the natural history of the disease. For these situations, a consultation 
should always be performed by a surgeon experienced in hepatic surgery.
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Removal of a portion of the liver is a challeng-
ing surgical procedure that has been performed
increasingly often over the past 20 years. Cur-
rently, surgery of the liver, biliary tract and
pancreas represents a significant portion of the
work of general surgeons and has already given
rise to specialized hepato–pancreato–biliary
surgical units. The question of whether this
branch of digestive surgery should become an
independent specialty remains open [1].
A short summary of the recent develop-
ments in liver surgery is necessary in order to
understand the history of this procedure and
what lies ahead. In fact, before the 1980s, the
approach to the liver was a surgical nightmare.
Most physicians practicing at that time, who
are now in their sixties, remember that period
and probably have a particular attitude toward
this surgical procedure. The difficulties in
achieving full control of the transacted surface,
paucity of the instruments and the lack of
knowledge of the intrahepatic vascular anat-
omy made liver resection very difficult. Fur-
thermore, the impossibility of performing an
early diagnosis of potentially treatable diseases
gave the procedure an aspect of futility. At that
time, most of the hepatic diseases were large,
symptomatic tumors or diffuse hepatocellular
carcinomas (HCC) found in patients with
advanced cirrhosis. The majority of the knowl-
edge regarding these diseases was derived from
postmortem examination of patients.
During the 1980s, something changed. First,
the increasingly widespread use of abdominal
ultrasonography (US) led to the possibility of
following those patients at risk of developing
malignancies of the liver amenable to surgery.
These categories of patients were represented
by those carrying hepatitis B or non-A non-B
hepatitis (later named hepatitis C) [2] and
patients already operated on for colonic cancer;
these groups were at risk of developing HCC or
liver metastases (LM), respectively.
On the other hand, the Vietnamese surgical
school of Thang Tung demonstrated that the
liver could be transected using the so-called
digitoclasia, fracturing the hepatic parenchyma
with the fingers in the search of medium and
large vessels to be securely tied and cut [3].
Since the early 1980s, the number of liver
resections has dramatically increased as a result
of improvements in diagnosis and the study of
diseases that are surgically treatable, and in
surgical techniques and armamentarium.
During the 1980s it became clear that a
defined group of patients are more prone to
develop lesions that could be treated with the
removal of limited portions of the liver. The
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first are those with chronic liver diseases, both viral and alco-
holic. The carcinogenetic action of the viral or toxic agent is
well defined. For this reason, they should be submitted to peri-
odical determination of the blood level of α-fetoprotein and to
the performance of abdominal ultrasonography. The debate is
ongoing regarding the frequency of the schedule [4,5] and con-
troversy remains over whether screening itself is worthwhile in
terms of decreasing the mortality rate related to HCC [6]. In
patients with chronic hepatic dysfunction, such management
can lead to the discovery of tumors with small dimensions that
are still amenable to therapies such as liver resection, liver
transplantation or percutaneous ablation.
On the other hand, patients already operated on for the
removal of adenocarcinomas located in the colon or rectum
must be followed up for the possible insurgence of LM, and the
liver is the most frequent target site. This follow-up is usually
performed by surgeons or by an oncologist, according to the
need for adjuvant chemotherapy, as suggested by the staging of
the primary tumor. Unfortunately, a considerable number of
these patients miss such a follow-up.
At present, patients are aware of possible differences in indi-
cations for surgery and on the modality of performance of sur-
gical treatment of liver diseases. They also know how to search
for these differences among qualified centers [7]. Thus, further
efforts should be made by the scientific community to obtain a
widespread rationalization of the treatments of these diseases.
Pre-operative work-up
Without any doubt, the widespread use of abdominal US
among radiologists, gastroenterologists, internal medicine phy-
sicians, surgeons and a variety of other health providers has led
to an increased detection of focal lesions of the liver. This pro-
cedure is easy to perform, noninvasive and has low costs. The
potential for portable instruments further increases applicabil-
ity. The major limit is perhaps represented by operator experi-
ence and skill. This instrument has benefited from the addition
of the Doppler study software and the possibility of using intra-
venous vascular contrast media. At present, ultrasonography
represents a formidable tool for first-line study of the liver and
recognition of possible diseases.
CT scanning and MRI are the fundamental tests used for the
determination of a possible indication for surgery. It is beyond
the scope of this review to discuss the indications for the per-
formance of both tests. Nevertheless, it should be mentioned
that both are able to correctly define the nature of a focal dis-
ease within the liver in most instances, enabling the location of
the tumor in relation to the glissonian pedicles and hepatic
veins to be determined. 3D imaging is increasingly used even in
peripheral hospitals. This is of paramount importance for sur-
geons planning intraoperative strategy. In addition, it is possi-
ble to evaluate the volume of the portion of parenchyma to be
removed by measuring them through the summation of each
2D area calculation. This could reduce the risk of postoperative
liver failure due to insufficient mass of healthy liver remaining
after extended hepatectomies.
Intraoperative ultrasonography remains the final step of
radiological evaluation and the ultimate tool for staging before
the performance of a resection. It has proved to be superior to
all other imaging systems in the study of the liver, both in terms
of sensitivity and specificity. The method can further define the
relationship between tumor and hepatic vessels, detect the pres-
ence of missed nodules, and guide the performance of the resec-
tion, thus verifying the direction of the transection plane.
Therefore, the presence of the instrument is mandatory in
every surgical liver center. It remains to be verified whether a
further improvement of its performances will be achieved with
the addition of contrast media.
Indication for liver resection
The vast majority of liver resections are performed for malig-
nancies. In a series of 1787 liver resections performed at the
University of Bologna (Bologna, Italy) since 1981, 1389
(77.7%) were on tumors. The main indications are HCC
(646; 36.1%) followed by metastases (626; 35.0%) and
tumors originating from the bile ducts (118; 6.6%).
A key point is the presence or absence of chronic hepatic dis-
ease in the liver to be operated on. Patients without any hepatic
disease, and thus with normal liver and hepatic function, can
be submitted with success to a large range of procedures and
even to extended or multiple resections. This is possible owing
to the well-known capacity for regeneration of the liver [8].
However, particular attention should be placed on the volume
of parenchyma remaining after resection. A number of differ-
ent formulas for calculating the total volume of the liver [9] and
the minimum acceptable volume have been evaluated [10,11].
Theoretically, a patient can be submitted to the removal of any
part of the liver with the preservation of such a calculated volume
and also the glissonian pedicles (including the afferent artery and
vein, and the efferent bile duct) and the hepatic veins of the
remaining parenchyma. A resection is defined as ‘anatomical’
when the portion of the liver removed corresponds to one or
more units of the segmental anatomy of the liver. A consensus on
the definition where anatomical resection was reached in 2000 in
Brisbane [12]. A resection is defined as ‘nonanatomical’ when the
resection plane does not follow the segmental anatomy.
Technical aspects
Without any doubt, the preferred abdominal incision for
accessing the liver is the J-shaped right subcostal laparotomy
that, in selected cases, can be extended to the left subcostal
configuring a Mercedes logo-shaped laparotomy.
With the introduction of several technical instruments as
tools for the surgeons, liver resection technique has changed
dramatically. In fact, digitoclasia has been replaced with the
kellyclasia [13], which is a method of fracturing the liver paren-
chyma using Kelly clamps [14]. Several aspects of the procedure
should be taken into consideration: the identification of the
tumor; the relationship of the tumor and the intrahepatic ves-
sels; the identification and the suture of the main intrahepatic
vessels; and the hemostasis of the cut surface.
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There are some obvious technical steps that influence short-
and long-term results, in particular for patients operated on for
oncological reasons; leaving a free margin of healthy paren-
chyma around the tumor to be removed in order to reduce the
risk of local recurrence is one. Furthermore, a significant
improvement in overall survival has recently been reported
with the increasingly widespread use of the so-called ‘anterior
approach’ to the right hepatic vein during the right hepatec-
tomy [15]. Compared with the extrahepatic isolation of the vein
during the conventional technique, the anterior approach has
been associated with significantly lower circulating plasma
albumin mRNA, a biological marker for circulating liver cells
possibly reflecting tumor cell dissemination during mobiliza-
tion and surgery at various stages of the resection. For this rea-
son, the anterior approach gives better operative and survival
outcomes compared with the conventional approach, and it
should be the preferred technique for major right hepatic
resections, at least for large HCC.
Kellyclasia probably represents the best way of performing a
liver resection, but it requires surgeons who are well trained in
the performance of the procedure. The search for extending the
number of centers attempting liver surgery has brought about
the development of new surgical tools for the performance of
such operations. The most popular devices that have been
claimed to facilitate bloodless transections include the ultra-
sonic dissector (Cavitron Ultrasonic Surgical Aspirator
[CUSA], Tyco Healthcare, MA, USA) using ultrasonic energy,
the Hydro-Jet® (Erbe, Tubingen, Germany) using a pressurized
jet of water, and the dissecting sealer (TissueLink, NH, USA)
using radiofrequency energy.
In a randomized trial, the clamp-crushing technique with
routine inflow occlusion was significantly associated with
decreased blood loss and shorter resection time when compared
with transection with CUSA, Hydro-Jet or dissecting sealer [16].
Furthermore, the concomitant cost analysis of the use of each
respective device indicated that the clamp-crushing technique is
the most cost-efficient strategy, regardless of the volume of liver
resection performed [16]. Clamp crushing was also superior to
ultrasonic dissection in terms of the overall quality of the hepa-
tectomy [17]. A plausible interpretation of this result is that sur-
geons experienced in hepatic resection will achieve comparable
levels of blood loss and transection time whether or not an
ultrasonic dissector is used [17].
The cost advantage of the kellyclasia technique is not only
attributed to very low equipment costs, but is also related to the
shorter resection time and lower blood loss with less need for
blood transfusion. The equipment costs of CUSA and Hydro-
Jet depend strongly on the number of cases per year, since both
devices require a large initial purchase with lower costs for dis-
posable material. The costs of these devices decrease by increas-
ing the number of cases performed. However, CUSA and
Hydro-Jet are three- to sixfold and two- to fourfold more
expensive compared with the clamp-crushing technique,
respectively. By contrast, the dissecting sealer only has costs of
the disposable material without the need to purchase a
machine, but costs were also three-times higher than the clamp-
crushing technique. Thus, the kellyclasia technique has the
highest cost-saving potential compared with other devices.
Even if the advantageous results of the clamp-crushing tech-
nique, such as shorter resection time and lower blood loss are
ignored, the cost of the equipment significantly favors the
clamp-crushing technique.
Some criticism arises from the fact that Hydro-Jet allows the
entrance of air bubbles into the intrahepatic vascular structure
during parenchyma transection, contributing to the difficulty
in performing intraoperative echography. CUSA, however,
can crush a wider range of liver parenchyma, which may lead
to the increased possibility of a tumor-positive surgical mar-
gin; however, these considerations have not been confirmed
by randomized controlled trials.
The most recently developed method, thermal technique by
radiofrequency ablation, has also been proposed to prevent
blood loss by inducing necrotic clotting of the defined resec-
tion plane. Final division of the parenchyma can be performed
using a scalpel or scissors. This method has been also claimed
to increase the margin of clearance, thus providing some onco-
logical advantage. Using a similar technique, some authors
have demonstrated a reduction in intraoperative blood loss.
On the other hand, radiofrequency precoagulation may be
associated with an increase in postoperative complications
related to increased necrosis of the liver parenchyma. It has
already been shown that, in effect, the radiofrequency resec-
tion technique allows parenchymal resection in a clean surgical
field, but it is more expensive and it is associated with a higher
rate of postoperative complications [18].
More recently, the harmonic scalpel (Ultracision, Ethicon,
Endo-surgery, Ohio, USA) and the Ligasure™ (Atlas, Vallylab,
Boulder, Tyco Healthcare) have both been proposed as useful
tools in the performance of hepatic resections. At present, there
are no data in the literature regarding their true utility. Neverthe-
less, the feeling is that they will not change the way that surgeons
already experienced in liver resections perform these procedures.
On the contrary, they could be of some help to general surgeons
who are already well trained in their use due to their application
in other abdominal procedures (open or laparoscopic).
Vascular control
It has already been demonstrated that reducing blood loss dur-
ing liver surgery improved short- and long-term results [19].
The liver owns a vascular inflow, represented by the hepatic
artery and the portal vein, and a vascular outflow, which is the
hepatic vein system. Controlling only the vascular inflow or
both the inflow and the outflow systems are the suggested ways
of reducing blood losses during parenchyma transection.
The most effective and easy way to apply this theory is by
clamping the hepatic pedicle, the so-called ‘Pringle maneuver’,
which completely stops the blood inflow occluding the portal
pedicle with the use of a vascular clamp [20]. Even if extremely
effective, clamping cannot be applied for a long period due to
the warm ischemic damage causing anoxia to the liver cells.
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Patients with chronic liver dysfunction are more susceptible to
these deleterious effects, and thus alternative ways of clamping
are needed.
The modification of continuous clamping with intermittent
clamping has been proposed successfully [21]. Intermittent
clamping of the portal triad is somehow related to ischemic pre-
conditioning (a brief period of ischemia followed by a short
interval of reperfusion), which is a nonpharmacologic strategy
to protect the liver from ischemic injuries. The rationale of
ischemic preconditioning is that cells are exposed to a limited
stress that triggers natural defense mechanisms against sub-
sequent ischemic injuries. In a recent review, intermittent
clamping and ischemic preconditioning are reported to be
highly and equally effective in minimizing postoperative injuries
to the liver, but intermittent clamping appears to be superior for
long periods of ischemia (≥75 min) [22].
A further step has been to verify the length of the interval of
the intermittent clamping [23]. It has then been used to ascer-
tain the safety of selectively clamping only the portion of liver
where the resection has to be performed to reduce the ischemic
time in the nonresected portion of the liver [24,25]. 
Pedicle clamping is useful for suddenly reducing the amount
of acute bleeding from the resected hepatic surfaces, but it is
not a mandatory step in the performance of a liver resection.
The maneuver must be in the armamentarium of all general
surgeons. Well-trained hepatic surgeons and/or a meticulous
technique of division of the liver parenchyma can render this
procedure completely unnecessary [26,27].
The control of the vascular outflow during resection is more
intriguing. The complete total vascular exclusion of the liver,
mainly proposed by Huguet [28], gained popularity in the early
1990s [29]. Its application is challenging from the technical
point of view and it quickly became evident that it is also
unnecessary in most cases [26]. The complete hepatic vascular
exclusion with preservation of the caval flow was also consid-
ered to be difficult to perform and did not gain much popular-
ity in the surgical community, even if it has defined
application [30]. Rather, a greater consensus has now been
reached on keeping the central venous pressure of the patient as
low as possible during the division of the parenchyma, thereby
reducing the possibility of bleeding from backflow [31].
One of the most controversial aspects of liver resection is the
treatment of the raw surface of the organ after the removal of the
surgical specimen. A number of hemostatic methods have been
evaluated as adjunctive procedures in hepatic resection. Topical
hemostatic agents have been used for this reason with varying
degrees of success. They include oxidized cellulose, absorbable
gelatin sponge, microfibrillar collagen and fibrin sealants pro-
duced with pooled plasma blood. Fibrin sealants have become
popular for improving perioperative hemostasis, reducing the
need for packed red blood cell transfusion, and in preventing
bile leakage. Nevertheless, it is thought that the way hepatec-
tomy is performed and the accuracy of the hemostasis reached
during parenchymal transaction are the major determinants of
the final results.
In fact, a prospective randomized trial reveals that the appli-
cation of fibrin sealant on the raw surface of the liver does not
seem justified [32]. Blood loss, transfusion, incidence of biliary
fistula and outcome were comparable to patients without fibrin
glue in this study. Therefore, discontinuation of routine use of
fibrin sealant would result in significant cost savings.
Complications
The definition of a specific complication in surgery is always
difficult to define and to reach a consensus on. For the purpose
of this review, we defined a complication as a condition or
event unfavorable to the patient’s health, causing irreversible
damage or requiring a change in therapeutic policy, including
prolonged hospital stay, after a liver resection. An accurate
classification of surgical complication has been recently
reported [33].
As in every surgical procedure, there are two different sets
of complications: those related to the performance of laparot-
omy alone and those specifically related to the performance of
a liver resection.
Postoperative liver failure
Under this view, most of the complications of liver resections
are directly related with the performance of the procedure
itself (TABLE 1). The most life threatening is the hepatic failure.
This is a grade IV–V surgical complication according to the
already reported classification [33]. The definition of postopera-
tive hepatic failure is not yet fully standardized. Without any
doubt, the death of the patient is the most extreme end point
to be taken into consideration. Nevertheless, the problem also
exists for the categorization of those patients who present tran-
sient abnormalities of hepatic function and who eventually
recover. Clinical and biological variables, such as ascites,
encephalopathy, jaundice, prolonged prothrombin time,
hyperbilirubinemia and hypoalbuminemia, are usual markers
of impaired liver function. There is neither a standardized def-
inition of postoperative liver failure based on these markers,
nor precise data on their correlation with postoperative mor-
tality (TABLE 2). The need for a standardized definition of post-
operative liver failure is important for the evaluation of techni-
cal improvements in different fields of liver surgery, such as
pre-operative portal vein deprivation and the result of different
methods of vascular clamping.
Impaired hepatic function after the operation can be second-
ary to several intraoperative factors: massive bleeding after or
during surgery with hypoperfusion of the organ, prolonged
clamping of the hepatic pedicle, incorrect fluid replacement
during laparotomy with secondary hypovolemia, removal of an
excessive amount of parenchyma and irreparable surgical lesion
of the vascular inflow or outflow during transection. Sepsis is
the leading cause of hepatic failure in the postoperative period.
For patients without any underlying liver disease, the possible
causes of a postoperative liver failure are mainly related to an
acute event that occurred during the operation or to the exces-
sive amount of parenchyma removed. For patients with a
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healthy liver, several indices have been proposed for calculating
the maximum amount of parenchyma that may be removed
with safety [10,37]. The total liver volume can be verified at CT
volumetry with the formula:
This formula was evaluated as the most helpful and reliable in a
recent meta-analysis [9].
It has been postulated that individuals with normal liver
function can undergo resection of up to 60% of nontumor-
ous parenchyma [10,37]; however, this limit can be extended
with a certain safety under several circumstances [11]. More
data and experience on the liver volume concept have
recently been accumulated from the experience gained with
the activity of liver transplantation from a living related
donor [38,39].
The possibility of performing the pre-operative embolization
of a main branch of the portal vein in order to induce the
hypertrophy of the controlateral lobe [40–42] or to perform itera-
tive resections [43,44] increases the possibility given to selected
patients of undergoing radical resections with a reduced risk of
postoperative liver failure.
The problem is more complex for patients with impaired
liver function. The etiology of possible postoperative liver fail-
ure varies according to the degree of a functional damage
already present in the liver for the contemporary presence of
the underlying disease. For these reasons, there have been sev-
eral attempts to identify clinical or mathematical tools capable
of predicting the insurgence of the complication.
Historically, the classification used the most for these
patients has been the Child-Pugh classification [45,46]. Despite
its widespread use, this classification lacks specificity, since two
of its components (the presence of ascites and encephalopathy)
are dependent on the observer and thus subject to criticism
and variability.
Other functional parameters have been proposed over the
years: the conversion of lidocaine to monoethylglycinexylidide
(MEGX) test [47], aminopyrine breath test, galactose-elimina-
tion capacity, arterial ketone body ratio and indocyanine green
(ICG) clearance rate have been widely tested [48]. The latter, in
particular, represents the gold standard for evaluation of
patients for surgery in Japan.
More recently, the Model for End-stage Liver Disease (MELD)
score has been applied with some success in this field [49]. Unfortu-
nately, none of these tests have such a high accuracy in predicting
the insurgence of postoperative liver failure.
Table 1. Postoperative complications in hepatic resections. 
HCC group Other liver 
malignancy group
Biliary malignancy 
group
LDLT donor 
group
Other benign 
diseases group
1056 hepatic resections
n 532 262 57 174 31
Patients with complications (%) 208 (39) 108 (41) 31 (54) 43 (25) 10 (32)
Major complications* (%) 15 (3) 20 (8) 16 (28) 8 (5) 0
Surgical intervention (%) 7 (1) 8 (3) 5 (9) 6 (3) 0
Bologna, 1787 resections
n 646 692 51 398
Patients with complications (%) 229 (35.4) 157 (22.7) 26 (50.9) 90 (22.6)
Major complications* (%) 58 (9.0) 57 (8.2) 11 (21.5) 11 (3.0)
Surgical intervention (%) 22 (3.4) 38 (5.5) 9 (17.6) 9 (2.2)
*Complications that required radiological or surgical interventions. Adapted from [34].
HCC: Hepatocellular carcinoma; LDLT: Living donor liver transplantation.
Total liver volume cm3( )
794.41– 1267.28 body surface area×( )+
=
Table 2. Biochemical parameters used in the definition of postoperative hepatic failure after liver resection. 
Study Bilirubine Prothrombine time Period Ref.
Imamura (2003) >5.0 mg/dl or >85 µmol/l <50% ≥3 consecutive days [34]
Balzan (2005) >3.0 mg/dl or >50 µmol/l <50% Postoperative day 5 [35]
Muller (2007) >7.0 mg/dl International normalized ratio >2.0 Postoperative peak [36]
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A hepatic vein pressure gradient of at least 10 mmHg has also
been shown to be a predictor of unresolved hepatic decompen-
sation after surgery [50]. The absence of portal hypertension and
normal bilirubin could be of some relevance in selecting the
best candidates for resection, but these data have not yet been
confirmed by other consistent studies.
The incidence of liver failure varies in the published series,
depending on the indication for surgery and the presence of
cirrhosis. For patients who underwent surgey for hepatic
tumors of any kind in noncirrhotic liver the mortality, glo-
bally, should be less than 1%. A higher mortality is reported
for patients operated on for tumors of bile duct confluence.
These latter patients are usually submitted to extended hepa-
tectomies, removal of the caudate lobe and the bile duct with
a Roux-en-Y hepaticojejunostomy. In this group of patients,
good results have been reported by the Japanese groups, with
postoperative mortality as low as 3–9.6% [51,52], while in
Western countries, a 7–10% postoperative mortality is quite
frequent [53].
In our series of 51 patients operated on for carcinoma of the
bile duct confluence, we observed an 11.7% operative mortality
(six patients).
For patients with HCC aroused in cirrhosis, a very low mor-
tality (ranging around 1%) can be achieved if restricted indica-
tions are followed [54]. When indications have been extended to
patients with severe comorbidities that are not amenable to
other, less invasive treatments, the postoperative mortality rate
quickly increases to 5–7% [55].
Biliary leakage
From a technical standpoint, biliary leakage is the most typical
technical complication after liver resection. One of the few def-
initions for bile leakage is a bilirubin level in the drainage fluid
that exceeds 5.0 mg/dl (>85 µmol/l) for more than 7 days or
intra-abdominal fluid collection showing a bilirubin level
greater than 5.0 mg/dl (>85 µmol/l) after the percutaneous
drain [34].
Bile leakage can originate from a separated bile duct with no
communication to the main biliary tree. In nonanatomical
hepatic resection, interruption of a bile duct can occur during
parenchymatous division. Another possibility is bile oozing
from crushed and exposed liver parenchymatous cells. A short
period of examination cannot detect bile oozing at the capillary
level. Such a microscopic bile leak might occur in some tran-
sient cases. On the other hand, a delayed bile leak is likely to be
related to infection.
Despite a significant decrease in the overall surgical com-
plication rate in hepatic resections, the rate of bile leakage
has not changed, with an incidence of 4.8–8.1% reported in
recent large series [56]. The incidence of postoperative bile
leakage has been reported to be similar among patients with
and without hepatitis or liver cirrhosis. High-risk procedure,
intraoperative blood loss and surgical time were associated
with the development of postoperative bile leakage using
univariate analysis [57].
The presence of bile, blood and necrotic tissue in a dead
space after hepatic resection provides the ideal environment
for bacterial growth; this environment impairs the normal
host defense mechanisms and predisposes the patient to sepsis,
liver failure and death.
There are at least four recommended methods of preventing
biliary complications after liver surgery: intraoperative cholang-
iography; spreading fibrin glue on the transected raw liver sur-
face; assessing bile duct patency by injecting air under ultra-
sonographic monitoring; and a bile leakage test. The role of the
fibrin glue in liver surgery has already been discussed [32]. A
randomized study suggested no advantage in using a bile leak-
age test to prevent bile leaks and it should, therefore, not be
used routinely during hepatic resection [58]. This result came
from a high-volume center of liver surgery, but whether this
may be reproduced by general surgeons must be evaluated. The
best way of preventing postoperative bile leakage remains the
meticulous management of the transected liver surface, rather
than performing a bile leakage test. 
In most patients, bile leakage resolves spontaneously, but
sometimes it is unremitting. Patients can usually be treated
conservatively. Bile leaks from small biliary stumps with some
communication to the main biliary tree will usually close spon-
taneously, with the restoration of peristalsis and papillary func-
tion. Bile leaks from the raw surface often involve concomitant
interruption of portal or arterial blood supply, and will also
subside with associated partial atrophy of the liver.
If effective drainage is achieved, it is usually sufficient to
observe the patient conservatively as long as careful manage-
ment of the drains against infection is maintained. Surgical
intervention is only required when a bile leak originates from
injury to a major duct, but re-operation is often complicated by
dense adhesions that render dissection and identification of the
leakage site difficult. Nonsurgical treatments, such as naso-
biliary drainage, are preferable to re-operation. However, biliary
decompression will not be effective when the leaking ducts do
not communicate with the common bile duct [59]. In these
cases, interventional treatment can be necessary (FIGURE 1).
Ascites
Ascites is a frequent complication observed after liver resec-
tion. There is no general agreement on even the definition of
the insurgence of ascites as a complication. The only consist-
ent definition includes the drainage of ascitic fluid of more
than 2 l/day for more than 3 days, drainage requiring para-
centesis after the abdominal drain was removed or postopera-
tive hospitalization of more than 30 days owing to ascites
control [34].
There are various causes for postoperative ascites: transient
impairment of the liver function secondary to the laparotomy
with hypoprotidemia and hypoalbuminemia, sections of lym-
phatic structures, the damage secondary to pedicle clamping
and modification of the global area of the portal blood distribu-
tion are all factors related to the phenomenon of fluid retention
after the operation.
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The problem is definitely more frequent after resection
in patients with chronic hepatitis or cirrhosis, but it can
often be observed in patients with healthy liver after
extended hepatectomies.
In our initial series of 264 carefully selected patients, the
presence of ascites was verified in 22.7% of the cases [54].
Treatment is usually medical, with infusion of fresh frozen
plasma, albumin and diuretics. If the presence of ascites is
part of hepatic decompensation, liver transplantation can be
necessary when the patient meets the indication.
Survival outcome
Postoperative mortality
The strongest indicator of the short-term clinical efficacy of
liver resections is the mortality rate. There are several ways to
define this short outcome measure. The classical method is to
count the number of patients who died within 30 days of the
date of surgery. The parameter has been extremely useful
since the management of more complex disease and the
extensive use of intensive care therapies led to a further exten-
sion of the possibility of patients surviving longer after sur-
gery. For this reason, the 30-day mortality has been widely
replaced by the 90-day or in-hospital mortality. These param-
eters give a more accurate vision of what happens after a liver
resection. Unfortunately, none of these parameters have been
defined as the gold standard, which is why one or more of
them are frequently found in the literature.
The mortality of liver resection was considerable when  this
surgery started becoming common practice. In some early series,
the percentage of patients who did not survive surgery ranged
from 15 to 20% and, in fact, these data led to the development
of alternative strategies for treating specific
diseases, such as HCC or cirrhosis. The
most efficient has been proven to be percu-
taneous radioablation. Most of the indica-
tions for resection and ablation overlap,
thus opening a strong competition between
the two different approaches.
In experienced centers, the mortality
can, today, be as low as zero, even in the
setting of a large number of procedures [34].
In our initial series of HCC, the hospi-
tal mortality was 4.9% for patients with
cirrhosis and 3.0% for patients without
cirrhosis, without any statistically signifi-
cant difference among the two groups.
These values dropped to 2.9 and 1.1%,
respectively, after 1992 [60].
In a systematic review of published
studies on surgical resections of LM from
colorectal cancer, the death rate within
30 days was reported as 0–6.6% (median:
2.8%). More frequent causes of death
were hepatic failure (18.4%), postopera-
tive hemorrhage (17.5%), generalized
sepsis (16.5%) and cardiac failure (11.7%) [61]. The mortal-
ity rates after extended hepatectomies for bile duct cancers
have already been reported.
Survival after resection of hepatocellular carcinoma
The natural history of HCC in cirrhosis foresees no survival
3 years after the initial diagnosis [62]. More recent data on the
natural history of the same disease revealed that selected
patients with extremely favorable prognostic factors can
achieve a 3-year survival up to 50% without any treatment [63].
Nevertheless, this is one of the diseases where surgical and
interventional therapies have significantly changed prognosis. 
The survival rate reported after resection is somewhat hetero-
geneous. A 5-year survival rate of 50–70% is currently
described at several centers [64]. The main problem with surgi-
cal resection is neoplastic recurrence, which complicates 70%
of cases at 5 years [65]. In fact, about a third of the patients are
alive and disease free 5 years after surgery [54]. The data report-
ing a 100% recurrence came from a single center and it has
never been confirmed by others [66].
It is difficult to discriminate between true recurrences (intrahe-
patic metastases) and the development of de novo tumors. From
genomic investigations it has been determined that 60–70% of
recurrences are intrahepatic metastases undetected at the time of
resection, whereas 30–40% are de novo tumors [67,68]. True recur-
rences typically emerge within 2 years of resection, and are usu-
ally associated with vascular invasion, satellites and poor differen-
tiation degree [65]. De novo tumors habitually occur late (>2 years
after resection). At present, there are no strategies (adoptive
immunotherapy, chemoembolization or internal radiation) that
consistently prevent recurrence.
Figure 1. The treatment of a biliary fistular after liver resection. 
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When recurrence is established, re-resection can be applied in
10–20% of cases, particularly those in which tumors are
thought to be de novo lesions. Salvage liver transplantation can
also be applied. Other treatments include percutaneous abla-
tion and transarterial chemoembolization. The combined treat-
ment of HCC recurrences significantly contributes to the
improvement of the results obtained in the most recent years.
Survival after resection of metastases from colorectal cancer
The natural history of LM from colorectal cancers is extremely
poor, but only a few studies dealt with the natural history of
untreated LM. A prospective study carried out during the 1980s
on 484 consecutive patients with untreated LM reported an
average survival rate of 31% at 1 year, 2.6% at 3 years and 0.9%
at 4 years. Factors independently influencing survival included
the extent of liver involvement, the presence of extrahepatic dis-
ease, the presence of metastases in the mesenteric lymph nodes,
carcinoembryonic antigen (CEA) level and the patient’s age [69].
On the contrary, the 5-year survival of patients submitted to
liver resection in more recent years ranges from 30 to 50%,
largely depending on the selection criteria. Our series, in which
44% of patients had multiple lesions (which are considered to be
a negative prognostic factor) reached a 5-year survival of 34% [70].
Even with the introduction of new and more efficient anti-
neoplastic drugs into the health market, the surgical removal of
LM remains the best treatment choice for these patients. There-
fore, the indication for liver resection for this disease receives the
compilation of specific guidelines [71]. There is no other therapy
that can achieve such an extension of patient survival. This is, in
fact, stated in most scientific literature on this topic [72].
It should also be underlined that the recurrence of the dis-
ease, intrahepatic or even extrahepatic, represents the most
common cause of death after liver resection. There are no
definitive strategies for reducing the percentages of patients
who develop recurrence and who have been validated from pro-
spective randomized trials. When recurrence is detected,
patients should be evaluated again by a surgeon and treated
accordingly either by re-operation or systemic chemotherapy.
Survival after repeated resections is as good after the first proce-
dure. In two recently published Japanese series, the percentage
of treatable patients with a second resection after the develop-
ment of an intrahepatic recurrence ranged from 14.3 to 25.4%,
and the 5-year survival was 49% [73,74].
Since the greater proportion of patients with metastases do
not have chronic diseases, all patients should be evaluated by a
surgeon for the indication for resection. Unfortunately, even
recent data from the literature reveal that only a minority of
patients with colorectal metastases underwent surgical removal
of the metastases [75].
Survival after resection of metastases from 
noncolorectal cancers
The indication for liver surgery in the presence of LM from
tumors originating in places other than the colon and rectum is
more controversial and less clear.
There is no doubt that an aggressive treatment of LM from
the neuroendocrine neoplasm can improve patient survival [76].
The small number of patients affected by this disease prevents
the identification of the long-term results that may be achieved
with liver resection.
On the other hand, in a series of 142 consecutive patients
submitted to curative liver resection for noncolorectal non-
neuroendocrine LM, we have reported a 5-year survival close
to 35% and a 5-year disease-free survival of 24% with no
postoperative mortality, compared with the dismal prognosis
of patients undergoing palliative procedures and almost no
survivors 3 years after diagnosis. A 5-year survival rate
between 20 and 37% might be expected in these patients after
curative liver resection [77]. Similar results have been recently
reported that confirm that liver resections on these hetero-
geneous diseases are safe and effective and can offer long-term
survival in selected patients [78,79]. Patients operated on for
LM from urologic and genital tumors can achieve a 50% sur-
vival 5 years after surgery. Furthermore, LM from pancreatic
cancers are no longer an absolute contraindication for surgery,
with a sustained long-term survival after hepatectomy.
Survival after resection of tumors of the biliary tract
Tumors from the biliary tract are difficult to manage owing to
their aggressive behavior, in particular those arising from the
confluence of the main bile ducts. These latter tumors are diffi-
cult to recognize and stage. Furthermore, because of their relative
paucity, there are very few referring centers and institutions.
Common treatment of these patients is limited to the inser-
tion of plastic or metallic stents to relieve jaundice. The survival
of these patients is usually limited to 1 year.
Surgical treatment of tumors of the main bile ducts, the so-
called Klatskin tumors, usually required right or left extended
hepatectomies, removal of the caudate lobe and the bile duct
and eventually a Roux-en-Y hepaticojejunostomy. This is a
complex surgical procedure that is usually performed in tertiary
referring centers.
Considering all of the 51 patients operated on at our insti-
tution, as well as those that died shortly after the operation,
the 3- and 5-year survivals are 47.3 and 34.1%, respectively.
Survival after resection of benign diseases
The surgical removal of benign diseases from the liver should
be carried out only in very carefully selected cases. The most
common instances are the documented growth of the lesion,
presence of symptoms and intraparenchymal or intraperitoneal
rupture or the diagnostic dilemma. Since these are truly benign
lesions, their ideal treatment should include no mortality and
the lowest rate of postoperative morbidity.
Expert commentary & five-year view
Liver resection is currently an established therapy for a large
number of hepatic diseases, particularly for those with malignant
origin. The study of a patient carrying a neoplastic disease ame-
nable to treatment with surgery requires a thorough evaluation,
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including hepatologic balance, oncological view when needed
and precise radiological mapping of the tumor and its relation-
ship with the major structures of the liver. The future will thus
drive the creation of specialized teams which, formally or not,
will cover a large spectrum of patients carrying liver diseases, irre-
spective of the need for medical or surgical therapy. This will be
facilitated by the strong relationships among the different aspects
of these illnesses.
The performance of a liver resection, particularly one that is
extended or complex, requires well-trained hepatic surgeons with
specific competence and skill in the performance of intraoperative
echography, parenchymal division, vascular control and hemo-
stasis. This can be achieved only after very specific and direct
training, which renders the procedure even more specialized.
The further improvement in indications and technique will
increase the safety of surgical intervention. The expertise and
necessary, specific competence to place indication for the inter-
vention will highlight the necesity of the creation of dedicated
departments exclusively devoted to the surgery and transplan-
tation of liver, which will have established and continuous col-
laborations with dedicated hepatologists, radiologists
and oncologists.
In certain countries hepato–pancreato–biliary units are
already a reality, but their number will hopefully increase over
the next few years. An alternative is provided by specific recog-
nition and certification of the hepato–pancreato–biliary surgical
activity performed by individuals or institutions by the relevant
scientific societies.
Key issues
• Liver resection is an established therapy for several neoplastic and benign hepatic diseases.
• Patients at risk of developing hepatocellular carcinoma and liver metastases should be submitted to regular radiological evaluation 
with abdominal ultrasound and CT scan.
• CT scan and MRI are indispensable tools in the evaluation of patients for surgery and in planning the performance of a liver resection.
• Among all the technical tools proposed for a safe division of the hepatic parenchyma, the so-called kellyclasia still appears to be 
most efficient, safe and cost saving.
• Vascular control of hepatic in- and outflow can reduce the amount of bleeding during resection.
• Postoperative liver failure remains the most life-threatening complication. The removal of an excessive amount of parenchyma and 
infections are the main causes of this complication.
• Biliary leakage is the most common technical complication, with an incidence of 4.8–8.1%.
• The possibility of performing portal vein embolization, simultaneous multiple resections and iterative resections has expanded the 
number of patients who are amenable to liver resections.
• A postoperative mortality rate of 0–5% is widely reported but, in experienced centers, the postoperative mortality can be as low as 0%.
• The 5-year survival after liver resection can be expected to be around 50% for hepatocellular carcinoma.
• The 5-year survival after liver resection for metastases from colorectal carcinoma ranges from 30 to 50%.
• The 5-year survival after extended liver resection for tumors of the main bile ducts ranges from 30 to 40%.
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